Please wait a minute...
European Journal of Gynaecological Oncology  2019, Vol. 40 Issue (5): 825-830    DOI: 10.12892/ejgo4848.2019
Original Research Previous articles | Next articles
Role of nesfatin in endometrial cancers
M. Szarszewska1, *(), J. Markowska1, A. Gryboś2, A. Marszalek3, V. Filas3, J. Żurawski4, M. Jóźwik5, A. Olejek6, W. Bednarek7, R. Mądry1, R. Jach8, A. Markowska9
1Department of Oncology, Gynaecological Oncology, Poznan University of Medical Sciences, Poznan, Poland
2Department of Gyneacology and Obstetrics, Faculty of Health Science, wroclaw Medical University, Poland
3Department of Tumour Pathology and Prophylaxis Poznan University of Medical Sciences, Greater Poland Cancer Centre, Poznan, Poland
4Department of Biology and Environmental Protections, Division of Immnobiochemistry, Poznan University of Medical Sciences, Poznan, Poland
5Chair and Department of Gynaecology, Gynaecologic Endocrinology and Obstetrics, University of warmia and Mazury, Olsztyn, Poland
6Department of Gynaecology Obstetrics and Gynaecology Oncology, Medical University of Silesia, Bytom, Poland
7Chair and Clinic of Gynaecological Oncology, Medical University, Lublin, Poland
8Gynecology and Obstetrics Department, Jagiellonian University Medical College, Kraków, Poland
9Department of Perinatology and Gynecology, Poznan University of Medical Sciences, Poznan, Poland
Download:  PDF(1854KB)  ( 142 ) Full text   ( 3 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

Aims: Endometrial cancers (ECs) represent a heterogeneous group of cancers with different types of histology, etiology, and prognosis. The largest risk factors for EC are obesity and diabetes. Nesfatin regulates food intake and glucose homeostasis. The aim of this multicentre study was closer recognition of nesfatin and other molecular factors in ECs. Materials and Methods: Using sections of paraffinembedded preparations and immunohistochemistry, the expression of nesfatin (NESF 1), estrogen receptors (ER α and β1), and progesterone receptor (PR) was examined in 146 cancer patients (115 EC type I and 33 type II). Results: In EC type I, a higher expression of PR, but lower ER β1 was found. No significant difference was detected in NESF 1 and ER α expression between the two types of ECs. ER α expression was higher in early stages of EC, and in more advanced cases ER β1 staining was weaker. In EC types I and II, a high expression of NESF 1 correlated with a high expression of ER α. Lower nesfatin expression correlated with low cells differentiation (grading) in EC type I. A tendency towards high expression of nesfatin was noted in patients with a lack of ER β1 expression. No correlation was found between the expression of NESF 1 and PR in any of the groups. Conclusions: The role of nesfatin in EC is still poorly understood. In EC type I, a high expression of NESF 1 seems to represent a favourable prognostic factor, while in type II its role is still unknown.

Key words:  Enodmetrial cancer      Nesfatin      Molecular factors     
Published:  10 October 2019     
*Corresponding Author(s):  M. SZARSZEWSKA     E-mail:  monika.szarszewska@gmail.com

Cite this article: 

M. Szarszewska, J. Markowska, A. Gryboś, A. Marszalek, V. Filas, J. Żurawski, M. Jóźwik, A. Olejek, W. Bednarek, R. Mądry, R. Jach, A. Markowska. Role of nesfatin in endometrial cancers. European Journal of Gynaecological Oncology, 2019, 40(5): 825-830.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo4848.2019     OR     https://ejgo.imrpress.com/EN/Y2019/V40/I5/825

No related articles found!
No Suggested Reading articles found!